There are clinical scenarios, such as those patients with clear contraindications for the use of systemic drugs (e.g. renal failure), in which topical or intralesional therapies would be better for the treatment in terms of side effects, but not in terms of clinical resolutions of leishmaniasis ulcers. Then, seems clear that with small lesions (e.g. 3 cms?